Document ID: chunk:federal_register_of_legislation:F2024L01389:schedule:1:p4
Version: federal_register_of_legislation:F2024L01389
Segment Type: schedule
Provision Reference: sch 1 (pt 4/66)
Character Range: 9946–12930

mg in 0.5 mL pre-filled syringe
omit from the column headed "Circumstances": C15439 substitute: C16050
[27] Schedule 1, Part 1, entry for Buprenorphine in each of the forms: Injection (modified release) 128 mg in 0.36 mL pre-filled syringe; and Injection (modified release) 160 mg in 0.45 mL pre-filled syringe
omit from the column headed "Circumstances": C15356 substitute: C16015
[28] Schedule 1, Part 1, entry for Buprenorphine in the form Injection (modified release) 300 mg in 1.5 mL pre-filled syringe
omit from the column headed "Circumstances": C15439 substitute: C16050
[29] Schedule 1, Part 1, entry for Buprenorphine in each of the forms: Tablet (sublingual) 400 micrograms (as hydrochloride); Tablet (sublingual) 2 mg (as hydrochloride); and Tablet (sublingual) 8 mg (as hydrochloride)
omit from the column headed "Circumstances": C15355 substitute: C16009
[30] Schedule 1, Part 1, entry for Buprenorphine with naloxone in each of the forms: Film (soluble) 2 mg (as hydrochloride)-0.5 mg (as hydrochloride); and Film (soluble) 8 mg (as hydrochloride)-2 mg (as hydrochloride)
omit from the column headed "Circumstances": C15355 substitute: C16009
[31] Schedule 1, Part 1, entry for Calcitriol
(a) omit:
Calcitriol  Capsule 0.25 microgram  Oral  APO-Calcitriol  TX  MP NP  C5089 C5114 C5255 C5401 C5402       P5089 P5114 P5255 P5401 P5402       100  3     100
Calcitriol  Capsule 0.25 microgram  Oral  APO-Calcitriol  TX  MP NP  C14231 C14259 C14287 C14296 C14322  P14231 P14259 P14287 P14296 P14322  200  3     100

(b) omit:
Calcitriol  Capsule 0.25 microgram  Oral  Kosteo  RW  MP NP  C5089 C5114 C5255 C5401 C5402       P5089 P5114 P5255 P5401 P5402       100  3     100
Calcitriol  Capsule 0.25 microgram  Oral  Kosteo  RW  MP NP  C14231 C14259 C14287 C14296 C14322  P14231 P14259 P14287 P14296 P14322  200  3     100

[32] Schedule 1, Part 1, entry for Cefazolin in the form Powder for injection 1 g (as sodium)
(a) omit from the column headed "Circumstances": C5861 C5882
(b) omit from the column headed "Circumstances": C5891
(c) insert in numerical order in the column headed "Circumstances": C15964 C16029 C16030
[33] Schedule 1, Part 1, entry for Cefazolin in the form Powder for injection 2 g (as sodium)
(a) omit from the column headed "Circumstances": C5826
(b) omit from the column headed "Circumstances": C5881 C5890
(c) insert in numerical order in the column headed "Circumstances": C15964 C16029 C16030
[34] Schedule 1, Part 1, entry for Cefepime in each of the forms: Powder for injection 1 g (as hydrochloride); and Powder for injection 2 g (as hydrochloride)
omit from the column headed "Circumstances": C5842 substitute: C16067
[35] Schedule 1, Part 1, entry for Cefotaxime [Authorised Prescriber: MP NP]
omit from the column headed "Circumstances": C5826 C5881 C5890  substitute: C15964 C16029 C16030
[36] Schedule 1, Part 1, entries for Ceftriaxone
substitute:
Ceftriaxone  Powder for injection 500 mg (as sodium)  Injection  Ceftriaxone‑AFT      AE